Q2 saw strong financial performance with 14.3% operating ROE and 15% book value growth, driven by disciplined specialty insurance expansion despite market softening. CAT losses and reserve releases were within expectations, and capital returns to shareholders increased.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.